InsiderTrades.com logo

ALA Insider Trading

Insider Ownership Percentage: 30.79%
Insider Buying (Last 12 Months): A$193,364.67
Insider Selling (Last 12 Months): A$0.00

Arovella Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Arovella Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Arovella Therapeutics Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 11/16/2021 10:05 AM ET

This chart shows the closing price history over time for ALA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Arovella Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/24/2025Elizabeth StonerInsiderBuy1,157,647A$0.08A$96,084.70
11/12/2025Debora BartonInsiderBuy1,013,333A$0.10A$97,279.97
3/27/2024Michael BakerInsiderBuy220,000A$0.14A$31,240.00
12/29/2023Michael BakerInsiderBuy587,824A$0.12A$67,599.76
See Full Table

SEC Filings (Institutional Ownership Changes) for Arovella Therapeutics (ASX:ALA)

6.05% of Arovella Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Arovella Therapeutics logo
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. The company product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
Read More on Arovella Therapeutics

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

A$207.51 million

P/E Ratio

N/A

Dividend Yield

1.23%

Beta

N/A

Who are the company insiders with the largest holdings of Arovella Therapeutics?

Arovella Therapeutics' top insider shareholders include:
  1. Debora Barton (Insider)
  2. Elizabeth Stoner (Insider)
  3. Michael Baker (Insider)
Learn More about top insider investors at Arovella Therapeutics.